MX2018014743A - Metodo para tratar fibrosis hepatica. - Google Patents

Metodo para tratar fibrosis hepatica.

Info

Publication number
MX2018014743A
MX2018014743A MX2018014743A MX2018014743A MX2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A
Authority
MX
Mexico
Prior art keywords
liver fibrosis
treating liver
fibrosis
treating
t2dm
Prior art date
Application number
MX2018014743A
Other languages
English (en)
Inventor
Miao Zhenhua
Charo Israel
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2018014743A publication Critical patent/MX2018014743A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Se proporciona un método para tratar fibrosis hepática con antagonistas de CCR2. La fibrosis hepática puede estar asociada con esteatohepatitis no alcohólica (NASH), enfermedad de hígado graso no alcohólico (NAFLD), cirrosis emergente, fibrosis hepática no cirrótica, diabetes mellitus tipo 2 (T2DM) o síndrome metabólico (MS).
MX2018014743A 2016-06-03 2017-06-02 Metodo para tratar fibrosis hepatica. MX2018014743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345086P 2016-06-03 2016-06-03
PCT/US2017/035628 WO2017210526A1 (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Publications (1)

Publication Number Publication Date
MX2018014743A true MX2018014743A (es) 2019-04-11

Family

ID=60479090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014743A MX2018014743A (es) 2016-06-03 2017-06-02 Metodo para tratar fibrosis hepatica.

Country Status (15)

Country Link
US (3) US10682344B2 (es)
EP (1) EP3463350B1 (es)
JP (2) JP2019517523A (es)
KR (1) KR102444366B1 (es)
CN (2) CN109475537A (es)
AU (1) AU2017274521B2 (es)
BR (1) BR112018074452A2 (es)
CA (1) CA3025671A1 (es)
ES (1) ES2966111T3 (es)
IL (1) IL263245B (es)
MX (1) MX2018014743A (es)
RU (1) RU2740902C2 (es)
SG (2) SG11201810602YA (es)
WO (1) WO2017210526A1 (es)
ZA (1) ZA201807992B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
AU2017274521B2 (en) * 2016-06-03 2021-08-19 Chemocentryx, Inc. Method of treating liver fibrosis
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PT3730487T (pt) 2016-06-13 2022-07-22 Gilead Sciences Inc Derivados de azetidina como moduladores de fxr (nr1h4)
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
IL266530B2 (en) * 2016-11-10 2024-09-01 Galmed Res And Development Ltd Use of Amcol for the treatment of fibrosis
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
AU2019287679B2 (en) * 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
CN112996490A (zh) * 2018-08-14 2021-06-18 阿沃林特有限公司 治疗原发性硬化性胆管炎的方法
JP2022510691A (ja) * 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
EP3965884A1 (en) 2019-05-08 2022-03-16 Aligos Therapeutics, Inc. Modulators of thr-beta and methods of use thereof
CA3148434A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt USE OF SGLT2 INHIBITORS TO TREAT PRIMARY BILIARY CHOLANGITIS
CN113274368B (zh) * 2020-02-20 2023-08-22 甘莱制药有限公司 一种用于治疗脂肪性肝炎的药物组合物及其制备方法
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
BR112023006143A2 (pt) * 2020-10-08 2023-05-09 Curome Biosciences Co Ltd Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118578A1 (en) * 2004-05-26 2005-12-15 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP2474532A1 (en) 2005-01-14 2012-07-11 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070219245A1 (en) 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
DE602007012261D1 (de) * 2006-07-14 2011-03-10 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
DK2175859T3 (da) * 2007-07-12 2012-06-18 Chemocentryx Inc Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
SG193216A1 (en) 2008-08-18 2013-09-30 Amgen Fremont Inc Antibodies to ccr2
MX2012006964A (es) * 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
CN103391931A (zh) * 2011-02-25 2013-11-13 辉瑞有限公司 治疗肝纤维化的方法
EP2755480B1 (en) * 2011-09-16 2021-03-31 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
AU2013258109A1 (en) * 2012-05-09 2014-10-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
EP3191100A4 (en) * 2014-09-12 2018-05-30 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
AU2017274521B2 (en) * 2016-06-03 2021-08-19 Chemocentryx, Inc. Method of treating liver fibrosis

Also Published As

Publication number Publication date
US10682344B2 (en) 2020-06-16
IL263245A (en) 2018-12-31
CN109475537A (zh) 2019-03-15
EP3463350B1 (en) 2023-09-13
JP2019517523A (ja) 2019-06-24
WO2017210526A1 (en) 2017-12-07
RU2018145459A (ru) 2020-07-09
SG10202012080UA (en) 2021-01-28
KR102444366B1 (ko) 2022-09-19
KR20190026687A (ko) 2019-03-13
IL263245B (en) 2021-09-30
AU2017274521B2 (en) 2021-08-19
ZA201807992B (en) 2023-10-25
US20200268727A1 (en) 2020-08-27
JP7431931B2 (ja) 2024-02-15
US20170348293A1 (en) 2017-12-07
JP2023022227A (ja) 2023-02-14
CN115154467A (zh) 2022-10-11
AU2017274521A1 (en) 2018-12-13
CA3025671A1 (en) 2017-12-07
BR112018074452A2 (pt) 2019-03-19
RU2018145459A3 (es) 2020-07-09
US20220313668A1 (en) 2022-10-06
EP3463350A1 (en) 2019-04-10
ES2966111T3 (es) 2024-04-18
US11357760B2 (en) 2022-06-14
RU2740902C2 (ru) 2021-01-21
EP3463350A4 (en) 2020-01-29
SG11201810602YA (en) 2018-12-28
CN115154467B (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
ZA201807992B (en) Method of treating liver fibrosis
MX2024010201A (es) Analogos de incretina y sus usos.
PH12020551024A1 (en) Incretin analogs and uses thereof
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
CR20210341A (es) Agonistas de glp-ir y usos de los mismos
NZ724740A (en) Treatment of nafld and nash
NZ729678A (en) Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
MX2019005533A (es) Tratamiento de la fibrosis.
AR104844A1 (es) Método para recubrimiento de un chupetín
EP3787618A4 (en) THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
WO2020009740A3 (en) Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EP3777860A4 (en) THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
EP3510014A4 (en) COMPOSITIONS AND METHODS FOR USE OF GAMMA KETOALDEHYD CATCHERS FOR TREATING, PREVENTING OR IMPROVING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD, OR DISEASES
MX2022000388A (es) Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4.
EA202091461A1 (ru) Пептиды для лечения и профилактики неалкогольной жировой болезни печени и фиброза
Fortington et al. Same, same but different… injury and safety promotion in rugby
WO2019221645A3 (en) Effect of balanites aegyptiaca on the regression of liver fibrosis and cirrhosis
Tohkairin Taxonomic and phylogeographic studies of Crystallichthys matsushimae (Pisces: Liparidae)
AU2018903354A0 (en) Nutritional Composition including Potassium for the treatment of Metabolic Syndrome
TH176687S (th) อาคารสำเร็จรูป
TH72696S1 (th) อาคารสำเร็จรูป
TH1701002228A (th) อะโกนิสต์ร่วมของกลูคากอนและ glp-1 รีเซปเตอร์
TH161687S (th) กระถาง
TH161690S (th) กระถาง
TH161691S (th) กระถาง